Alveolar Hemorrhage Caused by the Combination of Immune Checkpoint Inhibitors (ICIs) and Angiogenesis Inhibitors: The Underlying Long-Term Vascular Endothelial Growth Factor (VEGF) Inhibition.

Shijubou, Naoki; Sawai, Takeyuki; Hatakeyama, Taku; Munakata, Satoru; Yamazoe, Masami

Shijubou, Naoki; Sawai, Takeyuki; Hatakeyama, Taku; Munakata, Satoru; Yamazoe, Masami.

Afiliación

Shijubou N; Respiratory Medicine, Hakodate Municipal Hospital, Hakodate, JPN.
Sawai T; Respiratory Medicine, Hakodate Municipal Hospital, Hakodate, JPN.
Hatakeyama T; Respiratory Medicine, Hakodate Municipal Hospital, Hakodate, JPN.
Munakata S; Pathology, Hakodate Municipal Hospital, Hakodate, JPN.
Yamazoe M; Respiratory Medicine, Hakodate Municipal Hospital, Hakodate, JPN.

Cureus ; 14(3): e23272, 2022 Mar.

Article en En | MEDLINE | ID: mdl-35449623

Palabras clave

adverse events; anti-angiogenesis inhibitor; combination therapy; diffuse alveolar hemorrhage; immune checkpoint inhibitor; long-term vegf inhibition

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Cureus Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Cureus Año: 2022 Tipo del documento: Article